QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) CEO Presents Positive Phase IIa Proof of Concept Data in Advanced Breast Cancer
BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) Wednesday announced that it achieved proof of concept in the Phase IIa study of its lead clinical candidate, Bria-IMT(Trademarked), in advanced breast cancer. The company followed the after-hours news with a live webcast discussing the results, as presented by the company’s CEO Dr. Bill Williams. The data demonstrates promising anti-tumor activity of Bria-IMT in heavily pre-treated advanced breast cancer patients. BriaCell is now focusing on the combination study of Bria-IMT with pembrolizumab (Keytruda®, manufactured by Merck & Co., Inc.) or ipilimumab (Yervoy®, manufactured by Bristol-Myers Squibb Company) in patients with advanced breast cancer.…